Answers are grounded in this paper and cite their sources.
Squamous cell carcinoma of the lung (LUSC) arises in the upper large airways of the lung. While this location appears to be readily accessible, barriers such as mucus, cilia, and resident phagocytes can limit the efficacy of inhaled chemopreventive agents. Adding to the challenges, aerosolization methods such as nebulization often induce mechanical and thermal stresses that can compromise the integrity of therapeutics and vehicles. Here, we report the aerosolization of anisotropic Janus protein nanoparticles (JNPs) prepared via electrohydrodynamic (EHD) co-jetting for co-delivery of the apolar molecule fenretinide (4HPR) and the monoclonal antibody tocilizumab (TCZ). Our findings show that JNPs experienced a marginal increase in diameter after aerosolization, from 391.3 ± 152.5 nm to 419.9 ± 168.4 nm. Scanning electron microscopy (SEM) and super-resolution confocal microscopy results confirmed minimal changes to particle morphology and preservation of the bicompartmental nature of JNPs. Furthermore, a dose-dependent study revealed that JNPs exhibit good stability in aerosols, which can be leveraged to adjust and maximize payload regardless of particle concentration. We further confirmed the retention of the therapeutics' bioactivity in vitro after aerosolization based on activation of caspase-3-mediated apoptosis and reduction of IL-6-induced STAT3-mediated signaling (via p-STAT3). Aerosolization of JNPs combines stability and preservation of biological function, and their bicompartmental design can be leveraged for further applications in co-delivery of synergistic drug combinations.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: